Repository logo
 
Publication

l-proline supplementation improves nitric oxide bioavailability and counteracts the blood pressure rise induced by angiotensin II in rats

dc.contributor.authorLeal, Joana
dc.contributor.authorTeixeira-Santos, Luísa
dc.contributor.authorPinho, Dora
dc.contributor.authorAfonso, Joana
dc.contributor.authorCarvalho, Jorge
dc.contributor.authorde Lourdes Bastos, Maria
dc.contributor.authorAlbino-Teixeira, António
dc.contributor.authorFraga, Sónia
dc.contributor.authorSousa, Teresa
dc.date.accessioned2019-03-26T18:23:37Z
dc.date.available2019-03-26T18:23:37Z
dc.date.issued2018-11-10
dc.description.abstractWe evaluated whether l-proline (Pro) supplementation improves redox status and nitric oxide (NO) bioavailability and prevents or delays angiotensin II (AngII)-induced hypertension. Male Sprague-Dawley rats were distributed to four experimental groups: Pro + AngII (Pro-Ang), Pro + Saline (Pro-Sal), Vehicle + AngII (Veh-Ang) and Veh + Saline (Veh-Sal). Pro solution (2 g.kg-1·day-1) or water (vehicle) were orally administered, from day 0 to day 21. AngII (200 ng.kg-1.min-1) or saline were infused (s.c.) from day 7 to day 21. Systolic blood pressure (SBP) was measured by the tail-cuff method. From day 20-21, animals were kept on metabolic cages for 24h-urine collection. On day 21, urine and blood were collected for further quantification of redox status biomarkers, NO-related markers (urinary nitrates and nitrites, U-NOx; plasma asymmetric dimethylarginine, P-ADMA), metabolic and renal parameters. Pro prevented the AngII-induced SBP rise [mean (95% CI), Day 19: Pro-AngII, 137 (131; 143) vs. Veh-AngII, 157 (151; 163) mm Hg, P < 0.001]. Pro-AngII rats also had increased values of U-NOx, systemic and urinary total antioxidant status (TAS), urinary H2O2 and plasma urea, as well as reduced P-ADMA and unaltered urinary isoprostanes. Plasma Pro was inversely correlated with P-ADMA (r = -0.52, p = 0.0009) and positively correlated with urinary TAS (r = 0.55, p = 0.0005) which, in turn, was inversely correlated with P-ADMA (r = -0.56, p = 0.0004). Furthermore, urinary H2O2 values decreased across P-ADMA tertiles (p for linear trend = 0.023). These results suggest that Pro reduces P-ADMA levels and improves redox status, thereby increasing NO bioavailability and counteracting the AngII-induced SBP rise. H2O2 and TAS modulation by Pro may contribute to the reduced P-ADMA concentration.pt_PT
dc.description.sponsorshipThe authors acknowledge funding under project “NORTE-07-0124- FEDER-000001 – Neurodegenerative Disorders”, co-funded by North Portugal Regional Operational Programme (ON.2—O Novo Norte), under QREN (National Strategic Reference Framework) through FEDER (European Regional Development Fund), and by FCT (Fundação para a Ciência e a Tecnologia, Portugal). This study was also funded by the Program PT2020 (project 007265 -UID/QUI/50006/2013) supported by FCT and FEDER. Teresa Sousa and Sónia Fraga were funded by FCT and POPH/FSE (EC) (Human Potential Operational Programme/ European Social Fund (European Comission) (Ciência 2008 Contract). Teresa Sousa is currently funded by FCT (SFRH/BPD/112005/2015). Luísa Teixeira-Santos is funded by University of Porto/Faculty of Medicine and by ESF – European Social Fund, through NORTE2020 – North Portugal Regional Operational Programme (NORTE-08-5369- FSE-000011-Doctoral Programmes). Fig. 6. Mean (95% CI) plasma values of ADMA (A) and L-Arginine/ADMA ratio (B) for the different experimental groups (Veh-Sal, n=9; Pro-Sal, n=8; Veh-Ang, n=10; Pro-Ang, n=10) at the end of the experiment (day 21). Data were analysed with single measure parametric analysis (ANOVA), with 2 experimental factors (Pro and Ang) and a blocking factor. P-values obtained from the analysis for each factor and interaction of factors are presented in tables below the graphs. Results from multiple comparison procedures, performed as described in section 2.7, are indicated on the graph. J. Leal et al. Nitric Oxide 82 (2019) 1–11.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationNitric Oxide. 2019 Jan 1;82:1-11. doi: 10.1016/j.niox.2018.10.007. Epub 2018 Nov 10.pt_PT
dc.identifier.doi10.1016/j.niox.2018.10.007pt_PT
dc.identifier.issn1089-8603
dc.identifier.urihttp://hdl.handle.net/10400.18/6320
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1089860317302021?via%3Dihubpt_PT
dc.subjectAngiotensin IIpt_PT
dc.subjectAnimalspt_PT
dc.subjectBiological Availabilitypt_PT
dc.subjectBlood Pressurept_PT
dc.subjectHypertensionpt_PT
dc.subjectMalept_PT
dc.subjectNitric Oxidept_PT
dc.subjectProlinept_PT
dc.subjectRatspt_PT
dc.subjectRats, Sprague-Dawleypt_PT
dc.subjectDietary Supplementspt_PT
dc.subjectDoenças Cardio e Cérebro-vascularespt_PT
dc.titlel-proline supplementation improves nitric oxide bioavailability and counteracts the blood pressure rise induced by angiotensin II in ratspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/5876/UID%2FQUI%2F50006%2F2013/PT
oaire.citation.endPage11pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleNitric Oxide: Biology and Chemistrypt_PT
oaire.citation.volume82pt_PT
oaire.fundingStream5876
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.embargofctPolítica editorial da revistapt_PT
rcaap.rightsembargoedAccesspt_PT
rcaap.typearticlept_PT
relation.isProjectOfPublicationd7883dc7-6335-4f26-8bd0-e2ea4bb07c07
relation.isProjectOfPublication.latestForDiscoveryd7883dc7-6335-4f26-8bd0-e2ea4bb07c07

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
13_l-proline supplementation improves nitric oxide bioavailability.pdf
Size:
1.66 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: